{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoplasmacytoid+Lymphoma%2C+CLL&page=2",
    "query": {
      "condition": "Lymphoplasmacytoid Lymphoma, CLL",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoplasmacytoid+Lymphoma%2C+CLL&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T14:22:55.469Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02086591",
      "title": "A Phase II Study of Doxycycline in Relapsed NHL",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Diffuse Large B-Cell Lymphoma",
        "Mantle Cell Lymphoma Recurrent",
        "Lymphoma, Follicular",
        "Marginal Zone B-Cell Lymphoma",
        "Malignant Lymphoma - Lymphoplasmacytic",
        "Waldenstrom Macroglobulinemia",
        "Small Lymphocytic Lymphoma",
        "Chronic Lymphocytic Leukemia (CLL)",
        "T-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Doxycycline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Rochester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2014-03",
      "completion_date": "2015-11",
      "has_results": true,
      "last_update_posted_date": "2016-12-22",
      "last_synced_at": "2026-07-23T14:22:55.469Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02086591"
    },
    {
      "nct_id": "NCT00081809",
      "title": "A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma, Follicular",
        "Lymphoma, Small Lymphocytic"
      ],
      "interventions": [
        {
          "name": "autologous human tumor-derived HSPPC-96",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Agenus Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 35,
      "start_date": "2000-03",
      "completion_date": "2005-06",
      "has_results": false,
      "last_update_posted_date": "2023-09-28",
      "last_synced_at": "2026-07-23T14:22:55.469Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00081809"
    },
    {
      "nct_id": "NCT00496873",
      "title": "Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "Cytoxan",
          "type": "DRUG"
        },
        {
          "name": "Nipent",
          "type": "DRUG"
        },
        {
          "name": "Rituxan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2005-06",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2023-03-29",
      "last_synced_at": "2026-07-23T14:22:55.469Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00496873"
    },
    {
      "nct_id": "NCT01094860",
      "title": "Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "Nelarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 29,
      "start_date": "2010-06-08",
      "completion_date": "2018-08-09",
      "has_results": false,
      "last_update_posted_date": "2020-02-11",
      "last_synced_at": "2026-07-23T14:22:55.469Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01094860"
    },
    {
      "nct_id": "NCT03010358",
      "title": "Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Anemia",
        "B-Cell Prolymphocytic Leukemia",
        "Grade 1 Follicular Lymphoma",
        "Grade 2 Follicular Lymphoma",
        "Grade 3a Follicular Lymphoma",
        "Hairy Cell Leukemia",
        "Lymphoplasmacytic Lymphoma",
        "Mantle Cell Lymphoma",
        "Marginal Zone Lymphoma",
        "Recurrent Chronic Lymphocytic Leukemia",
        "Recurrent Small Lymphocytic Lymphoma",
        "Refractory Chronic Lymphocytic Leukemia",
        "Refractory Small Lymphocytic Lymphoma",
        "Richter Syndrome"
      ],
      "interventions": [
        {
          "name": "Entospletinib",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Obinutuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Alexey Danilov, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2017-07-17",
      "completion_date": "2021-04-29",
      "has_results": true,
      "last_update_posted_date": "2023-08-08",
      "last_synced_at": "2026-07-23T14:22:55.469Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03010358"
    },
    {
      "nct_id": "NCT02722668",
      "title": "UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Leukemia",
        "Acute Myeloid Leukemia",
        "Acute Lymphoblastic Leukemia/Lymphoma",
        "Burkitt's Lymphoma",
        "Natural Killer Cell Malignancies",
        "Chronic Myelogenous Leukemia",
        "Myelodysplastic Syndrome",
        "Large-cell Lymphoma",
        "Hodgkin Lymphoma",
        "Multiple Myeloma",
        "Relapsed Chronic Lymphocytic Leukemia",
        "Relapsed Small Lymphocytic Lymphoma",
        "Marginal Zone B-cell Lymphoma",
        "Follicular Lymphoma",
        "Lymphoplasmacytic Lymphoma",
        "Mantle-cell Lymphoma",
        "Prolymphocytic Leukemia",
        "Bone Marrow Failure Syndromes",
        "Myeloproliferative Neoplasms/Myelofibrosis",
        "Biphenotypic/Undifferentiated/Prolymphocytic Leukemias",
        "MRD Positive Leukemia",
        "Leukemia or MDS in Aplasia",
        "Relapsed T-Cell Lymphoma",
        "Relapsed Multiple Myeloma",
        "Plasma Cell Leukemia"
      ],
      "interventions": [
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "MMF",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "TBI",
          "type": "RADIATION"
        },
        {
          "name": "Umbilical cord blood cell infusion",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ATG",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "BIOLOGICAL"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "Up to 75 Years"
      },
      "enrollment_count": 15,
      "start_date": "2017-05-15",
      "completion_date": "2024-02-22",
      "has_results": true,
      "last_update_posted_date": "2025-07-04",
      "last_synced_at": "2026-07-23T14:22:55.469Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02722668"
    },
    {
      "nct_id": "NCT03601819",
      "title": "Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma, T-Cell, Cutaneous",
        "Lymphoma, T-Cell, Peripheral",
        "Chronic Lymphocytic Leukemia",
        "Lymphoproliferative Disorders",
        "Waldenstrom Macroglobulinemia",
        "Lymphoplasmacytic Lymphoma",
        "Mantle Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Pacritinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Michigan Rogel Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2019-05-15",
      "completion_date": "2020-07-17",
      "has_results": false,
      "last_update_posted_date": "2021-01-22",
      "last_synced_at": "2026-07-23T14:22:55.469Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03601819"
    },
    {
      "nct_id": "NCT03314974",
      "title": "Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Leukemia",
        "Acute Myeloid Leukemia",
        "Acute Lymphoblastic Leukemia",
        "Lymphoma",
        "Chronic Myelogenous Leukemia",
        "Plasma Cell Leukemia",
        "Myeloproliferative Neoplasms",
        "Myelofibrosis",
        "Myelodysplasia",
        "Refractory Anemia",
        "High Risk Anemia",
        "Chronic Lymphocytic Leukemia",
        "Small Lymphocytic Lymphoma",
        "Marginal Zone B-Cell Lymphoma",
        "Follicular Lymphoma",
        "Lymphoplasmacytic Lymphoma",
        "Mantle-Cell Lymphoma",
        "Prolymphocytic Leukemia",
        "Diffuse Large Cell Non Hodgkins Lymphoma",
        "Lymphoblastic Lymphoma",
        "Burkitt Lymphoma",
        "High Grade Non-Hodgkin's Lymphoma, Adult",
        "Multiple Myeloma",
        "Juvenile Myelomonocytic Leukemia",
        "Biphenotypic/Undifferentiated/Prolymphocytic Leukemias",
        "MRD Positive Leukemia",
        "Natural Killer Cell Malignancies",
        "Acquired Bone Marrow Failure Syndromes"
      ],
      "interventions": [
        {
          "name": "HSCT with TBI Regimen",
          "type": "BIOLOGICAL"
        },
        {
          "name": "HSCT with Non-TBI Regimen",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "Up to 60 Years"
      },
      "enrollment_count": 300,
      "start_date": "2018-03-30",
      "completion_date": "2028-06-10",
      "has_results": false,
      "last_update_posted_date": "2026-06-25",
      "last_synced_at": "2026-07-23T14:22:55.469Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03314974"
    },
    {
      "nct_id": "NCT02661035",
      "title": "Allo HSCT Using RIC for Hematological Diseases",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myelogenous Leukemia",
        "Acute Lymphocytic Leukemia",
        "Chronic Myelogenous Leukemia",
        "Plasma Cell Leukemia",
        "Myelodysplastic Syndromes",
        "Chronic Lymphocytic Leukemia",
        "Small Lymphocytic Lymphoma",
        "B-Cell Lymphoma",
        "Follicular Lymphoma",
        "Lymphoplasmacytic Lymphoma",
        "Mantle-Cell Lymphoma",
        "Prolymphocytic Leukemia",
        "Lymphoblastic Lymphoma",
        "Burkitt's Lymphoma",
        "Non-Hodgkin's Lymphoma",
        "Multiple Myeloma",
        "Myeloproliferative Syndromes",
        "Hematological Diseases"
      ],
      "interventions": [
        {
          "name": "Allopurinol",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "ATG",
          "type": "DRUG"
        },
        {
          "name": "TBI",
          "type": "RADIATION"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "MMF",
          "type": "DRUG"
        },
        {
          "name": "Peripheral Blood Stem Cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Related or Unrelated Bone Marrow Cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "BIOLOGICAL"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "Up to 75 Years"
      },
      "enrollment_count": 156,
      "start_date": "2017-03-09",
      "completion_date": "2023-05-29",
      "has_results": false,
      "last_update_posted_date": "2023-09-21",
      "last_synced_at": "2026-07-23T14:22:55.469Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02661035"
    },
    {
      "nct_id": "NCT01732913",
      "title": "Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Indolent Non-Hodgkin's Lymphomas"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Idelalisib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 295,
      "start_date": "2013-01-16",
      "completion_date": "2016-05-18",
      "has_results": true,
      "last_update_posted_date": "2018-11-16",
      "last_synced_at": "2026-07-23T14:22:55.469Z",
      "location_count": 32,
      "location_summary": "Huntsville, Alabama • Chandler, Arizona • Duarte, California + 28 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01732913"
    }
  ]
}